thioctic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4732 1077-28-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • thioctic acid
  • lipothion
  • thioctacid
  • thioctsan
  • tioctacid
  • (RS)-Lipoic acid
  • alpha-lipoic acid
  • alpha lipoic acid
  • lipoic acid
An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
  • Molecular weight: 206.32
  • Formula: C8H14O2S2
  • CLOGP: 2.39
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -2.96
  • ROTB: 5

Drug dosage:

DoseUnitRoute
0.60 g O
0.60 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.21 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 52
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,MAPK8,PRKDC,STK33,TEK,TGFBR1,TTK 17
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic necrosis 198.00 64.06 31 255 6407 90621754
Hepatic encephalopathy 174.45 64.06 31 255 13741 90614420
Hepatotoxicity 153.86 64.06 34 252 45808 90582353
Hepatic cirrhosis 127.33 64.06 31 255 63222 90564939
Drug-induced liver injury 116.36 64.06 31 255 90287 90537874
Drug interaction 85.91 64.06 32 254 276421 90351740

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Basal cell carcinoma 59.62 49.28 17 347 22716 42598255

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic necrosis 162.60 50.35 31 656 9891 110578721
Hepatic encephalopathy 130.27 50.35 31 656 28225 110560387
Hepatotoxicity 118.81 50.35 34 653 63366 110525246
Hepatic cirrhosis 107.81 50.35 32 655 67594 110521018
Drug-induced liver injury 97.43 50.35 34 653 120033 110468579
Drug interaction 68.95 50.35 41 646 500142 110088470

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AX01 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Various alimentary tract and metabolism products
MeSH PA D000975 Antioxidants
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:78675 fundamental metabolite
CHEBI has role CHEBI:176497 geroprotector

Related Drugs by ATC class:

A16AX Various alimentary tract and metabolism products 23 drugs
anethole trithionedoxecitinedoxribtimineeliglustatfosdenopteringivosiranglycerol phenylbutyratelonafarniblumasiranmigalastatmiglustatnedosiran show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetic peripheral neuropathy indication 424736006
Obstruction of bile duct contraindication 30144000
Low blood pressure contraindication 45007003
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.05 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Acetylcholinesterase Enzyme IC50 9 CHEMBL
SUMO-activating enzyme Enzyme IC50 5.32 CHEMBL
TAR DNA-binding protein 43 Cytosolic other IC50 4.70 CHEMBL
Bifunctional protein GlmU Enzyme IC50 5.41 CHEMBL

External reference:

IDSource
D00086 KEGG_DRUG
4021484 VUID
N0000148863 NUI
4021443 VANDF
4021484 VANDF
CHEBI:16494 CHEBI
LPA PDB_CHEM_ID
CHEMBL33864 ChEMBL_ID
CHEMBL134342 ChEMBL_ID
DB00166 DRUGBANK_ID
6417 RXNORM
107951 MMSL
163055 MMSL
163060 MMSL
23416 MMSL
397220 MMSL
NOCODE MMSL
d06655 MMSL
006470 NDDF
70496003 SNOMEDCT_US
715405004 SNOMEDCT_US
C0023791 UMLSCUI
D008063 MESH_DESCRIPTOR_UI
864 PUBCHEM_CID
4822 IUPHAR_LIGAND_ID
73Y7P0K73Y UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Strovite OneCaplets HUMAN PRESCRIPTION DRUG LABEL 20 0642-0207 TABLET 15 mg ORAL unapproved drug other 14 sections
Vita-Rx Diabetic Vitamin HUMAN PRESCRIPTION DRUG LABEL 14 69677-050 CAPSULE, GELATIN COATED 150 mg ORAL unapproved drug other 5 sections